JPWO2022155476A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022155476A5 JPWO2022155476A5 JP2023543164A JP2023543164A JPWO2022155476A5 JP WO2022155476 A5 JPWO2022155476 A5 JP WO2022155476A5 JP 2023543164 A JP2023543164 A JP 2023543164A JP 2023543164 A JP2023543164 A JP 2023543164A JP WO2022155476 A5 JPWO2022155476 A5 JP WO2022155476A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- recombinant
- protein
- vector
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100031673 Corneodesmosin Human genes 0.000 claims description 24
- 101710139375 Corneodesmosin Proteins 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 21
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 20
- 230000002163 immunogen Effects 0.000 claims description 13
- 238000012217 deletion Methods 0.000 claims description 12
- 230000037430 deletion Effects 0.000 claims description 12
- 239000002773 nucleotide Substances 0.000 claims description 12
- 125000003729 nucleotide group Chemical group 0.000 claims description 12
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 claims description 10
- 108091026890 Coding region Proteins 0.000 claims description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 8
- 108700026244 Open Reading Frames Proteins 0.000 claims description 8
- 238000012986 modification Methods 0.000 claims description 8
- 230000004048 modification Effects 0.000 claims description 8
- 150000007523 nucleic acids Chemical group 0.000 claims description 8
- 239000002245 particle Substances 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 208000025721 COVID-19 Diseases 0.000 claims description 5
- 108010027410 Adenovirus E3 Proteins Proteins 0.000 claims description 4
- 241001678559 COVID-19 virus Species 0.000 claims description 4
- 241001135572 Human adenovirus E4 Species 0.000 claims description 4
- 230000003053 immunization Effects 0.000 claims description 4
- 238000003780 insertion Methods 0.000 claims description 4
- 230000037431 insertion Effects 0.000 claims description 4
- 238000006467 substitution reaction Methods 0.000 claims description 4
- 208000037847 SARS-CoV-2-infection Diseases 0.000 claims description 3
- 230000028993 immune response Effects 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 239000000443 aerosol Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000010076 replication Effects 0.000 claims description 2
- 238000000034 method Methods 0.000 description 7
- 229960005486 vaccine Drugs 0.000 description 3
- 229940022962 COVID-19 vaccine Drugs 0.000 description 2
- 238000013504 emergency use authorization Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000016379 mucosal immune response Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000009781 safety test method Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163138221P | 2021-01-15 | 2021-01-15 | |
| US63/138,221 | 2021-01-15 | ||
| PCT/US2022/012530 WO2022155476A1 (en) | 2021-01-15 | 2022-01-14 | Replication-competent adenovirus type 4 sars-cov-2 vaccines and their use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024503482A JP2024503482A (ja) | 2024-01-25 |
| JPWO2022155476A5 true JPWO2022155476A5 (https=) | 2025-01-22 |
| JP2024503482A5 JP2024503482A5 (https=) | 2025-01-22 |
Family
ID=80222188
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023543164A Pending JP2024503482A (ja) | 2021-01-15 | 2022-01-14 | 複製可能アデノウイルス４型ｓａｒｓ－ｃｏｖ－２ワクチンおよびそれらの使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240293532A1 (https=) |
| EP (1) | EP4277656A1 (https=) |
| JP (1) | JP2024503482A (https=) |
| KR (1) | KR20230132816A (https=) |
| CN (1) | CN117412769A (https=) |
| AU (1) | AU2022208035A1 (https=) |
| CA (1) | CA3205052A1 (https=) |
| WO (1) | WO2022155476A1 (https=) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5643578A (en) | 1992-03-23 | 1997-07-01 | University Of Massachusetts Medical Center | Immunization by inoculation of DNA transcription unit |
| US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
| WO2010044921A2 (en) * | 2008-06-03 | 2010-04-22 | Vaxin Inc. | Intranasal administration of receptor-binding ligands or genes encoding such ligands as a therapeutic regimen for mitigating infections caused by respiratory pathogens |
| CN102549152B (zh) * | 2009-07-31 | 2015-11-25 | 帕克斯瓦克斯股份有限公司 | 基于腺病毒的载体 |
| KR102104650B1 (ko) * | 2011-03-21 | 2020-04-24 | 알티뮨 인크. | 급속 및 지속적 면역학적제제-치료제 |
| MX2022009460A (es) * | 2020-02-04 | 2022-12-16 | Curevac Ag | Vacuna contra el coronavirus. |
| WO2021160346A1 (en) * | 2020-02-13 | 2021-08-19 | Institut Pasteur | Nucleic acid vaccine against the sars-cov-2 coronavirus |
| CN111983226A (zh) * | 2020-03-25 | 2020-11-24 | 新加坡国立大学 | SARSr-CoV抗体的检测 |
| MX2022015132A (es) * | 2020-05-29 | 2023-03-08 | CureVac SE | Vacunas combinadas a base de acidos nucleicos. |
-
2022
- 2022-01-14 AU AU2022208035A patent/AU2022208035A1/en active Pending
- 2022-01-14 EP EP22703165.5A patent/EP4277656A1/en active Pending
- 2022-01-14 KR KR1020237027608A patent/KR20230132816A/ko active Pending
- 2022-01-14 US US18/271,901 patent/US20240293532A1/en active Pending
- 2022-01-14 CA CA3205052A patent/CA3205052A1/en active Pending
- 2022-01-14 WO PCT/US2022/012530 patent/WO2022155476A1/en not_active Ceased
- 2022-01-14 CN CN202280010458.8A patent/CN117412769A/zh active Pending
- 2022-01-14 JP JP2023543164A patent/JP2024503482A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ertl et al. | Novel vaccine approaches | |
| CN109843323B (zh) | 用于黄病毒疫苗接种的组合物和方法 | |
| JP2026026092A5 (https=) | ||
| US10059747B2 (en) | Crimean-congo haemorrhagic fever virus antigenic composition | |
| JPWO2021155323A5 (https=) | ||
| CN116096406A (zh) | 针对呼吸道合胞病毒感染的疫苗组合 | |
| JP2001523729A (ja) | Ｌｔｂアジュバントを含むワクチン | |
| Kiyono et al. | Nasal vaccines for respiratory infections | |
| JP2015536134A5 (https=) | ||
| JP2020530765A5 (https=) | ||
| CN113226364A (zh) | 组合物和方法 | |
| WO2011059334A1 (en) | Use of newcastle disease virus-based vector for inducing an immune response in mammals | |
| JP2001516583A5 (https=) | ||
| JP2023503058A (ja) | ヘモフィルス・パラスイスに対する新規ワクチン | |
| JP2025084850A (ja) | ハンタウイルス抗原性組成物 | |
| AU2026201375A1 (en) | Treatment of urticaria | |
| CN101455846B (zh) | 脱乙酰壳聚糖递送系统组装的结核基因疫苗及其制备和应用 | |
| US20240207385A1 (en) | Compositions comprising self-assembling vaccines and methods of using the same | |
| US20240299528A1 (en) | A dna plasmid sars-corona virus-2/covid-19 vaccine | |
| JPWO2022155476A5 (https=) | ||
| USRE49514E1 (en) | Methods for treating plague | |
| CN110229219B (zh) | 一种新型的呼吸道合胞病毒疫苗抗原的制备方法及其用途 | |
| CN110382518B (zh) | 用于血清型a型口蹄疫病毒的嵌合疫苗 | |
| Lee et al. | Coronavirus disease 2019 (COVID-19) vaccine platforms: how novel platforms can prepare us for future pandemics: a narrative review | |
| CA3076263C (en) | Synthetic hemagglutinin as universal vaccine against infection by type b influenza viruses (ibv) |